Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Short Interest Update

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) was the target of a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 7,045 shares, a growth of 1,819.6% from the June 15th total of 367 shares. Based on an average daily trading volume, of 8,423 shares, the short-interest ratio is presently 0.8 days.

Clinuvel Pharmaceuticals Price Performance

Shares of CLVLY stock traded up $0.08 during mid-day trading on Friday, reaching $7.24. The stock had a trading volume of 1,042 shares, compared to its average volume of 2,799. The stock’s 50-day moving average price is $6.87 and its two-hundred day moving average price is $7.31. Clinuvel Pharmaceuticals has a 52-week low of $5.98 and a 52-week high of $9.00.

Clinuvel Pharmaceuticals Company Profile

Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.

The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.